Facebook
Twitter
LinkedIn
Forward
Sarcopenic obesity presents numerous risks to health and quality of life.
|
This webinar re-playing the popular session from the Obesity Medicine Conference 2021 provides a brief overview of FDA-approved anti-obesity medications (AOM’s).
|
The global COVID-19 pandemic has turned our patient’s lives and routines upside down.
|
Patients and Primary Care Clinicians face numerous difficulties in providing effective, affordable weight loss and maintenance programs.
|
During this webinar, Dr.
|
As the choices available for anti-obesity pharmacotherapy increase, clinicians are faced with options for addressing key clinical scenarios.
|
In June of 2023 the AASLD updated the nomenclature for NAFLD to Metabolic dysfunction-Associated Steatotic Liver Disease(MASLD).
|
Obesity is a chronic, serious life threatening disease, but treatments exist. Obesity is associated with an increased risk of CVD and CV-associated mortality.
|
Obesity is one of the leading causes of preventable death. Obesity-related increases metabolic and cardiovascular risk occur at a lower body mass index in Asian adults.
|
Join Dr. Angela Fitch for this Obesity Care Week webinar to dissect and raise awareness of the complexities of obesity from a medical perspective.
|